Osborne Clarke advised OncoDNA on friendly public tender offer for IntegraGen

International law practice Osborne Clarke advised OncoDNA on the successful finalisation of a public tender offer for a majority of shares of IntegraGen. The transaction was initiated in July 2020 and OncoDNA announced its successful conclusion yesterday (16 November) after receiving the official communication from the French Financial Markets Authority (AMF).

Following the conclusion of the public tender, OncoDNA is the majority shareholder of IntegraGen, with 63.71% of the capital and 64.26% of the effective voting rights.

This transaction combines OncoDNA's expertise in the field of precision medicine in oncology and IntegraGen's know-how in DNA sequencing and bioinformatic analyses. The alliance of the two companies will provide a unique range of services to clinical professionals, oncologists, researchers and biologists around the world, with a view to improving the treatment of patients suffering from advanced cancer who can benefit from a holistic solution combining laboratory tests and software in the field of oncology.

"The Board of Directors of OncoDNA and I would like to thank the shareholders of IntegraGen for their confidence. OncoDNA and IntegraGen can now begin a new phase of development based on the solid foundation that we have been building over the past few years. The management teams of both companies have already started the process of integrating their solutions portfolio and their respective teams. We are confident that this new step in the history of our company will allow us to grow even more, and to create value for our employees and shareholders, and more importantly for our clients, oncologists and patients," said Jean-Pol Detiffe, Founder of OncoDNA.

"This is an important day for IntegraGen, for our customers and for our employees", adds Bernard Courtieu, the CEO of IntegraGen. "The success of this transaction guarantees optimal collaboration and integration between the teams in order to achieve our ambition to provide our clients with the best genomic analysis and interpretation tools. This alliance will strengthen our position in the market through the implementation of our growth plan. We look forward to executing this plan and working in concert with OncoDNA. "

OncoDNA was advised by ODDO BHF (financial advisor) and White & Case provided legal advice alongside Osborne Clarke.  The Osborne Clarke team was headed by partner Hadrien Chef and included Tonya Aelbrecht, Violette Keppenne, Chloé Ponsart, Marie Canivet, Thierry Viérin, Benjamin Docquir and Olivier Lambillon.

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada, Japan, South Africa or any other jurisdiction in which it would be unlawful to do so. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.